Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
 Annual Meeting 2016 - EconoTimes)
WEST LAFAYETTE, Ind., April 11, 2016 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
The presentation materials will be available on Endocyte’s website following presentation at the conference.
Presentations are as follows:
| Abstract #: | 262 |
| Title: | Combination therapy of folate-targeted chemotherapeutics with anti-PD-1 antibody against folate receptor-positive tumors in immunocompetent murine models |
| When: | Sunday, April 17, 1 p.m. – 5 p.m. EDT |
| Session Title: | Combination Chemotherapy |
| Location: | Halls G-J, Poster Section 15 |
| Abstract #: | 3035 |
| Title: | Development and characterization of CCK2R-targeted SMDCs and identification of GIST as a potential therapeutic indication |
| When: | Tuesday, April 19, 8 a.m. – 12 p.m. EDT |
| Session Title: | Novel Targets and Pathways |
| Location: | Halls G-J, Poster Section 17 |
| Abstract #: | 3754 |
| Title: | Pre-clinical studies of a highly potent Folate receptor targeted DNA crosslinking agent |
| When: | Tuesday, April 19, 1 p.m. – 5p.m. EDT |
| Session Title: | Novel Antitumor DNA-Reactive Agents |
| Location: | Halls G-J, Poster Section 16 |
| Abstract #: | 4735 |
| Title: | Designing Novel Warheads for Targeted Therapies: SAR and Efficient Strategies for Synthesis of Analogs of Tubulysin |
| When: | Wednesday, April 20, 8 a.m. – 12 p.m. EDT |
| Session Title: | HDAC, Methyltransferase Inhibitors, and Novel Anticancer Agents |
| Location: | Halls G-J, Poster Section 17 |
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
